Protara Therapeutics (TARA) Interest Expenses (2013 - 2026)
Protara Therapeutics (TARA) posted quarterly Interest Expenses of $8.8 million for Q1 2026, up 109.33% year-over-year from $4.2 million in Q1 2025, and up 2376.75% quarter-over-quarter from $357000.0 in Q4 2025.
Protara Therapeutics (TARA) Interest Expenses (2013 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Interest Expenses for 14 consecutive years, with $8.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 109.33% year-over-year to $8.8 million; the TTM figure through Mar 2026 stood at $8.8 million (up 109.33% YoY), while the FY2025 annual figure was $83.6 million, up 15.31% from the prior year.
- Interest Expenses grew to $8.8 million in Q1 2026 per TARA's latest filing, from $357000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $8.8 million in Q1 2026 and bottomed at $239000.0 in Q4 2023.
- Historically, Interest Expenses has averaged $2.5 million across 5 years, with a median of $1.4 million in 2023.
- On a YoY basis, Interest Expenses climbed as much as 2782.0% in 2022 and fell as far as 85.59% in 2022.
- Protara Therapeutics' Interest Expenses stood at $332000.0 in 2022, then decreased by 28.01% to $239000.0 in 2023, then jumped by 38.91% to $332000.0 in 2024, then rose by 7.53% to $357000.0 in 2025, then jumped by 2376.75% to $8.8 million in 2026.
- Business Quant data shows TARA's Interest Expenses at $8.8 million in Q1 2026, $357000.0 in Q4 2025, and $5.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - | 2.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.99 Mn |
| Jun 30, 2026 | 2.99 Mn |
| Mar 31, 2026 | 8.84 Mn |
| Mar 31, 2026 | 8.84 Mn |
| Dec 31, 2025 | 357,000.00 |
| Dec 31, 2025 | 357,000.00 |
| Sep 30, 2025 | 5.05 Mn |
| Sep 30, 2025 | 5.05 Mn |
| Jun 30, 2025 | 4.38 Mn |
| Jun 30, 2025 | 4.38 Mn |
| Mar 31, 2025 | 4.22 Mn |
| Mar 31, 2025 | 4.22 Mn |
| Dec 31, 2024 | 332,000.00 |
| Dec 31, 2024 | 332,000.00 |
| Sep 30, 2024 | 5.39 Mn |
| Sep 30, 2024 | 5.39 Mn |
| Jun 30, 2024 | 1.43 Mn |
| Jun 30, 2024 | 1.43 Mn |
| Mar 31, 2024 | 3.68 Mn |
| Mar 31, 2024 | 3.68 Mn |